Search Results - "Angiotensin II Type 1 Receptor Blockers/therapeutic use"
-
1
Authors: et al.
Source: J Cachexia Sarcopenia Muscle
Journal of Cachexia, Sarcopenia and Muscle, Vol 16, Iss 3, Pp n/a-n/a (2025)
Soendenbroe, C, Heisterberg, M F, Andersen, J L, Kjaer, M & Mackey, A L 2025, ' Serum C-Terminal Agrin Fragment With Acute and Long-Term Exercise and Angiotensin II Type I Receptor Blockade ', Journal of Cachexia, Sarcopenia and Muscle, vol. 16, no. 3, e13832 . https://doi.org/10.1002/jcsm.13832Subject Terms: Male, Angiotensin II Type 1 Receptor Blockers/therapeutic use, angiotensin II type I receptor, aging, QM1-695, Resistance Training, Diseases of the musculoskeletal system, Middle Aged, Receptor, Angiotensin, Type 1/metabolism, Agrin/blood, RC925-935, Exercise/physiology, Human anatomy, Humans, biomarker, neuroprotection, Original Article, Peptide Fragments/blood, hypertrophy, neuromuscular system, Biomarkers/blood, Aged
File Description: application/pdf
-
2
Authors:
Subject Terms: Aminobutyric Acids/administration &, dosage, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Antihypertensive Agents/therapeutic use, Blood Pressure/drug effects, Dose-Response Relationship, Drug, Humans, Hypertension/drug therapy, Hypertension/physiopathology, Neprilysin/antagonists &, inhibitors, Tetrazoles/administration &, Tetrazoles/therapeutic use, Valine/analogs &, derivatives, Valine/therapeutic use
Relation: Lancet; 1474-547X[electronic], 0140-6736[linking]; https://iris.unil.ch/handle/iris/56768; serval:BIB_6782143F849B
Availability: https://iris.unil.ch/handle/iris/56768
https://doi.org/10.1016/S0140-6736(10)60363-7 -
3
Authors: et al.
Subject Terms: Albuminuria/drug therapy, Albuminuria/economics, Angiotensin II Type 1 Receptor Blockers/administration & dosage, Angiotensin II Type 1 Receptor Blockers/economics, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Antihypertensive Agents/administration & dosage, Antihypertensive Agents/economics, Antihypertensive Agents/therapeutic use, Biphenyl Compounds/administration & dosage, Biphenyl Compounds/economics, Biphenyl Compounds/therapeutic use, Cohort Studies, Cost Savings, Creatinine/blood, Diabetes Mellitus, Type 2/drug therapy, Type 2/economics, Diabetic Nephropathies/drug therapy, Diabetic Nephropathies/economics, Follow-Up Studies, Humans, Hypertension/complications, Hypertension/drug therapy, Hypertension/economics, Life Expectancy, Markov Chains, Practice Guidelines as Topic, Switzerland, Tetrazoles/administration & dosage, Tetrazoles/economics
File Description: application/pdf
Relation: Swiss Medical Weekly; https://iris.unil.ch/handle/iris/47692; serval:BIB_387B5794018D; 000238642700003
Availability: https://iris.unil.ch/handle/iris/47692
-
4
Authors: et al.
Subject Terms: Aged Angiotensin II Type 1 Receptor Blockers/*therapeutic use Blood Pressure/drug effects Diuretics/*therapeutic use Double-Blind Method Drug Therapy, Combination Female Follow-Up Studies Humans Hydrochlorothiazide/*therapeutic use Hypertension/*drug therapy/physiopathology Imidazoles/*therapeutic use Male Middle Aged Severity of Illness Index Tetrazoles/*therapeutic use Treatment Outcome
Relation: Journal of Human Hypertension; https://iris.unil.ch/handle/iris/41954; serval:BIB_3E4CA14675DC; 000236040500009
-
5
Authors: et al.
Contributors: et al.
Subject Terms: Adult, Aged, Amlodipine/adverse effects, Amlodipine/therapeutic use, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Antihypertensive Agents/adverse effects, Antihypertensive Agents/therapeutic use, Blood Pressure/drug effects, Calcium Channel Blockers/therapeutic use, Diabetes Mellitus, Type 2/complications, Double-Blind Method, Drug Combinations, Female, Humans, Hypertension/complications, Hypertension/drug therapy, Imidazoles/adverse effects, Imidazoles/therapeutic use, Male, Medication Adherence, Middle Aged, Perindopril/adverse effects, Perindopril/therapeutic use, Tetrazoles/adverse effects, Tetrazoles/therapeutic use, Treatment Outcome
Relation: Journal of Hypertension; https://iris.unil.ch/handle/iris/210490; serval:BIB_C026E9F13CC7
-
6
Authors: et al.
Subject Terms: Aged, Anemia/drug therapy, Anemia/etiology, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Cross-Sectional Studies, Dose-Response Relationship, Drug, Drug Resistance, Drug Therapy, Combination, Erythropoietin, Recombinant/administration &, dosage, Recombinant/therapeutic use, Female, Follow-Up Studies, Humans, Hypertension/drug therapy, Hypertension/etiology, Kidney Failure, Chronic/therapy, Male, Middle Aged, Renal Dialysis/adverse effects, Retrospective Studies, Treatment Outcome
Relation: Journal of Nephrology; https://iris.unil.ch/handle/iris/148364; serval:BIB_C7E37BCC2D53; 000236676400015
Availability: https://iris.unil.ch/handle/iris/148364
-
7
Authors: et al.
Source: Nakano, A, Vinter, N, Egstrup, K, Svendsen, M L, Schjødt, I & Johnsen, S P 2019, 'Association between process performance measures and 1-year mortality among patients with incident heart failure : a Danish nationwide study', European heart journal. Quality of care & clinical outcomes, vol. 5, no. 1, pp. 28-34. https://doi.org/10.1093/ehjqcco/qcy041
Nakano, A, Vinter, N, Egstrup, K, Svendsen, M L, Schjødt, I & Johnsen, S P 2019, ' Association between process performance measures and 1-year mortality among patients with incident heart failure : a Danish nationwide study ', European Heart Journal-Quality of Care and Clinical Outcomes, vol. 5, no. 1, pp. 28-34 . https://doi.org/10.1093/ehjqcco/qcy041
Nakano, A, Vinter, N, Egstrup, K, Svendsen, M L, Schjødt, I & Johnsen, S P 2019, 'Association between process performance measures and 1-year mortality among patients with incident heart failure : a Danish nationwide study', European Heart Journal-Quality of Care & Clinical Outcomes, vol. 5, no. 1, pp. 28-34. https://doi.org/10.1093/ehjqcco/qcy041Subject Terms: Male, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Performance measures, Denmark, Adrenergic beta-Antagonists, Heart failure, Angiotensin-Converting Enzyme Inhibitors, 03 medical and health sciences, 0302 clinical medicine, Patient Education as Topic, Humans, Registries, Mortality, Aged, Aged, 80 and over, Heart Failure, Clinical registries, Process Assessment (Health Care), Process Assessment, Health Care, Middle Aged, Adrenergic beta-Antagonists/therapeutic use, Denmark/epidemiology, Exercise Therapy, 3. Good health, Heart Failure/diagnostic imaging, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Treatment Outcome, Echocardiography, Practice Guidelines as Topic, Female, Guideline Adherence, Angiotensin II Type 1 Receptor Blockers, Follow-Up Studies
Access URL: https://academic.oup.com/ehjqcco/article-pdf/5/
1 /28/27287162/qcy041.pdf
https://pubmed.ncbi.nlm.nih.gov/30204858
https://vbn.aau.dk/da/publications/2a4eb5e4-9261-46df-adc3-588035c2d259
http://www.scopus.com/inward/record.url?scp=85059243975&partnerID=8YFLogxK
https://doi.org/10.1093/ehjqcco/qcy041
https://europepmc.org/article/MED/30204858
https://www.ncbi.nlm.nih.gov/pubmed/30204858
https://vbn.aau.dk/da/publications/association-between-process-performance-measures-and-1year-mortality-among-patients-with-incident-heart-failure(2a4eb5e4-9261-46df-adc3-588035c2d259).html
https://academic.oup.com/ehjqcco/article/5/1 /28/5094885
https://vbn.aau.dk/da/publications/association-between-process-performance-measures-and-1 -year-morta
https://pubmed.ncbi.nlm.nih.gov/30204858/
https://portal.findresearcher.sdu.dk/da/publications/1a5f958d-5db0-4f33-b81f-18501089c9c5
https://doi.org/10.1093/ehjqcco/qcy041
https://portal.findresearcher.sdu.dk/da/publications/1a5f958d-5db0-4f33-b81f-18501089c9c5
https://pure.au.dk/portal/en/publications/571d3eb4-5b3b-4f79-95f9-3c23342c0188
http://www.scopus.com/inward/record.url?scp=85059243975&partnerID=8YFLogxK
https://doi.org/10.1093/ehjqcco/qcy041 -
8
Authors: et al.
Contributors: et al.
Source: Arq Bras Cardiol
Arquivos Brasileiros de Cardiologia, Vol 115, Iss 1, Pp 17-28 (2020)
Arquivos Brasileiros de Cardiologia v.115 n.1 2020
Arquivos Brasileiros de Cardiologia
Sociedade Brasileira de Cardiologia (SBC)
instacron:SBC
Repositório Institucional da UNESP
Universidade Estadual Paulista (UNESP)
instacron:UNESP
Arquivos Brasileiros de Cardiologia, Volume: 115, Issue: 1, Pages: 17-28, Published: 07 AUG 2020
Arquivos Brasileiros de Cardiologia, Issue: ahead, Published: 11 MAY 2020Subject Terms: 0301 basic medicine, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Doenças Cardiovasculares, Angiotensin II Type 1 Receptor Blockers/ therapeutic use, Diet, High-Fat, Losartan/therapeutic use, 03 medical and health sciences, 0302 clinical medicine, Dieta Hiperlipídica/métodos, Diseases of the circulatory (Cardiovascular) system, Animals, Obesity, Rats, Wistar, Losartan/uso terapêutico, Ratos, 2. Zero hunger, Artigo Original, Diet, High-fat/methods, Papillary Muscles, Physical Functional Performance, Myocardial Contraction, Diet, Rats, 3. Good health, Obesidade, Cardiovascular Diseases, RC666-701, High-fat/methods, Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico
File Description: text/html
Access URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384332
https://pubmed.ncbi.nlm.nih.gov/32401842
https://doaj.org/article/ab6d8e3a8394423c8504a9eb7a212be8
https://www.ncbi.nlm.nih.gov/pubmed/32401842
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384332
https://www.scielo.br/j/abc/a/ZvhBCqVXCCmGNrQdnFSHbCL/
https://pubmed.ncbi.nlm.nih.gov/32401842/
https://europepmc.org/article/PMC/PMC8384332
https://repositorio.unesp.br/handle/11449/201155
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2020000800017
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2020000800017&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2020005007204&lng=en&tlng=en -
9
Authors:
Source: Pharmacopsychiatry. 50:233-247
Subject Terms: 0301 basic medicine, Brain - drug effects, Mental Disorders, Brain, Angiotensin-Converting Enzyme Inhibitors, Mental disorders - drug therapy, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Angiotensin-converting enzyme inhibitors - therapeutic use, Animals, Humans, Angiotensin II type 1 receptor blockers - therapeutic use, Angiotensin II Type 1 Receptor Blockers
Access URL: https://pubmed.ncbi.nlm.nih.gov/28641333
https://www.ncbi.nlm.nih.gov/pubmed/28641333
https://www.thieme-connect.com/products/ejournals/pdf/10.1055/s-0043-112345.pdf
https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0043-112345
https://europepmc.org/article/MED/28641333
https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0043-112345 -
10
Contributors: et al.
Subject Terms: Aged, Angiotensin II Type 1 Receptor Blockers / therapeutic use, Angiotensin-Converting Enzyme Inhibitors / therapeutic use, Dyslipidemias / complications, Dyslipidemias / drug therapy, Female, Humans, Male, Middle Aged, Myocardial Infarction / complications, Myocardial Infarction / drug therapy, Myocardial Infarction / mortality, Myocardial Infarction / surgery, Registries, Republic of Korea, Stents, Treatment Outcome, dyslipidemia, myocardial infarction, renin-angiotensin system
Relation: ANATOLIAN JOURNAL OF CARDIOLOGY; J00137; https://ir.ymlib.yonsei.ac.kr/handle/22282913/190227; T9992020452
-
11
Authors: et al.
Source: Andrologia. 48:840-846
Subject Terms: Male, germ cells, Turkey, losartan, Apoptosis, orchiectomy, Rats, Sprague-Dawley, 0302 clinical medicine, Testis, Varicocele, oxidative stress, rat, 10. No inequality, adult, drug effect, apoptosis, nitrosative stress, Immunohistochemistry, 3. Good health, immunohistochemistry, histopathology, Angiotensin II Type 1 Receptor Blockers/*therapeutic use, Animals, Apoptosis/*drug effects, Disease Models, Animal, Germ Cells/*physiology, Humans, In Situ Nick-End Labeling, Infertility, Male/*drug therapy/etiology/metabolism, Losartan/*therapeutic use, Nitric Oxide Synthase Type III/metabolism, Orchiectomy, Rats, Spermatogenesis/physiology, Testis/*cytology/pathology/surgery, Varicocele/complications/*metabolism, varicocele, Nitric Oxide Synthase Type III, animal experiment, Article, Losartan, animal tissue, 03 medical and health sciences, male, testis injury, controlled study, Spermatogenesis, Infertility, Male, endothelial nitric oxide synthase, nonhuman, animal model, scoring system, germ cell, TUNEL assay, spermatogenesis, Germ Cells, Angiotensin II Type 1 Receptor Blockers
Access URL: https://pubmed.ncbi.nlm.nih.gov/27373273
https://www.ncbi.nlm.nih.gov/pubmed/27373273
http://europepmc.org/abstract/MED/27373273
https://pubmed.ncbi.nlm.nih.gov/27373273/
https://onlinelibrary.wiley.com/doi/abs/10.1111/and.12638
https://www.europeanurology.com/article/S1569-9056(16)15074-2/fulltext/effects-of-losartan-on-experimental-varicocele-induced-testicular-germ-cell-apoptosis
https://www.sciencedirect.com/science/article/pii/S1569905616150742
https://www.eusupplements.europeanurology.com/article/S1569-9056(16)15074-2/fulltext
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/9441 -
12
Authors: et al.
Contributors: et al.
Source: European Journal of Cardio-Thoracic Surgery. 50:1045-1052
Subject Terms: Male, Heart Valve Prosthesis Implantation/methods, Blotting, Western, Calcinosis/prevention & control, Rabbit, Intravenous implantation, Losartan, 03 medical and health sciences, 0302 clinical medicine, Losartan/therapeutic use, Degenerative calcification, Animals, Animal model, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Vascular Patency, Bioprosthesis, Heart Valve Prosthesis Implantation, Blotting, Calcinosis, Heart Valve Prosthesis, 3. Good health, Bioprosthetic heart valve, Rabbits, Western, Angiotensin II Type 1 Receptor Blockers
Access URL: https://academic.oup.com/ejcts/article-pdf/50/6/1045/8582270/ezw191.pdf
https://pubmed.ncbi.nlm.nih.gov/27261074
https://pubmed.ncbi.nlm.nih.gov/27261074/
https://academic.oup.com/ejcts/article/50/6/1045/2726561
https://academic.oup.com/ejcts/article/50/6/1045/2726561/The-angiotensin -II -type -1 -receptor -blocker
https://ir.ymlib.yonsei.ac.kr/handle/22282913/153093
https://www.ncbi.nlm.nih.gov/pubmed/27261074
http://europepmc.org/abstract/MED/27261074 -
13
Authors: et al.
Contributors: et al.
Source: Clinical Therapeutics. 38:1485-1497
Subject Terms: Pyrimidines/therapeutic use, Adult, Male, hypertension, Benzimidazoles/adverse effects, Tetrazoles/therapeutic use, Tetrazoles, Biphenyl Compounds/therapeutic use, Blood Pressure, Blood Pressure/drug effects, Dose-Response Relationship, Young Adult, 03 medical and health sciences, candesartan, 0302 clinical medicine, Double-Blind Method, Antihypertensive Agents/therapeutic use, Humans, Angiotensin II Type 1 Receptor Blockers/therapeutic use, angiotensin receptor blocker, Antihypertensive Agents, Aged, Hypertension/physiopathology, Dose-Response Relationship, Drug, Pyrimidines/adverse effects, Antihypertensive Agents/adverse effects, Biphenyl Compounds, Biphenyl Compounds/adverse effects, fimasartan, Middle Aged, 6. Clean water, 3. Good health, Pyrimidines, Benzimidazoles/therapeutic use, Hypertension, Benzimidazoles, Female, Angiotensin II Type 1 Receptor Blockers/adverse effects, Drug, Tetrazoles/adverse effects, Essential Hypertension, Angiotensin II Type 1 Receptor Blockers, Hypertension/drug therapy
File Description: 1485~1497
-
14
Authors: et al.
Source: Eur Heart J
McMurray, J, Packer, M, Desai, A, Gong, J, Greenlaw, N, Lefkowitz, M, Rizkala, A, Shi, V, Rouleau, J, Solomon, S, Swedberg, K, Zile, M R, Andersen, K, Arango, J L, Arnold, M, Bĕlohlávek, J, Böhm, M, Boytsov, S, Burgess, L, Cabrera, W, Chen, C-H, Erglis, A, Fu, M, Gomez, E, Gonzalez, A, Hagege, A-A, Katova, T, Kiatchoosakun, S, Kim, K-S, Bayram, E, Martinez, F, Merkely, B, Mendoza, I, Mosterd, A, Negrusz-Kawecka, M, Peuhkurinen, K, Ramires, F, Refsgaard, J, Senni, M, Sibulo, A S, Silva-Cardoso, J, Squire, I, Starling, R C, Vinereanu, D, Teerlink, J R, Wong, R & PARADIGM-HF Committees and Investigators 2015, 'A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure', European Heart Journal, vol. 36, no. 7, pp. 434-9. https://doi.org/10.1093/eurheartj/ehu455Subject Terms: Male, Cardiac & Cardiovascular Systems, heart failure, Tetrazoles, Angiotensin-Converting Enzyme Inhibitors, angiotensin II, Enalapril, Enalapril/therapeutic use, Natriuretic peptides, Angiotensin II, Aminobutyrates, Middle Aged, ACTIVE-CONTROL TRIALS, Angiotensin Receptor Antagonists/therapeutic use, 3. Good health, Hospitalization, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Drug Combinations, Treatment Outcome, Tetrazoles/therapeutic use, NON-INFERIORITY, ENALAPRIL, SURVIVAL, CAPTOPRIL, Valsartan, Female, Life Sciences & Biomedicine, Benzimidazoles/therapeutic use, Angiotensin II Type 1 Receptor Blockers/therapeutic use, INHIBITION, Heart failure, Angiotensin Receptor Antagonists, Humans, FASTTrack Clinical Research, Hospitalization/statistics & numerical data, Aged, Heart Failure, Science & Technology, MORTALITY, Biphenyl Compounds, Heart Failure/drug therapy, Placebo Effect, RANDOMIZED-TRIAL, Aminobutyrates/therapeutic use, MYOCARDIAL-INFARCTION, Cardiovascular System & Cardiology, Benzimidazoles, LOSARTAN, natriuretic peptides, Angiotensin II Type 1 Receptor Blockers
File Description: application/pdf
Access URL: https://academic.oup.com/eurheartj/article-pdf/36/7/434/17899386/ehu455.pdf
https://pubmed.ncbi.nlm.nih.gov/25416329
https://eprints.gla.ac.uk/99985/1 /99985.pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328198
https://academic.oup.com/eurheartj/article/36/7/434/494403
https://core.ac.uk/display/42021981
https://gup.ub.gu.se/records/fulltext/207465/207465.pdf
https://www.ncbi.nlm.nih.gov/pubmed/25416329
https://escholarship.org/uc/item/7qc3468q
https://academic.oup.com/eurheartj/article/36/7/434/494403
https://doi.org/10.1093/eurheartj/ehu455
https://acuresearchbank.acu.edu.au/item/8v728/a-putative-placebo-analysis-of-the-effects-of-lcz696-on-clinical-outcomes-in-heart-failure
https://pure.au.dk/portal/en/publications/d7a22c42-6a55-49d6-8cd0-10d34e3d13a3
https://doi.org/10.1093/eurheartj/ehu455 -
15
Authors: et al.
Contributors: et al.
Source: Clinical Therapeutics. 36:1412-1421
Subject Terms: Pyrimidines/therapeutic use, Adult, Male, hypertension, Tetrazoles/therapeutic use, 0211 other engineering and technologies, Tetrazoles, Biphenyl Compounds/therapeutic use, Blood Pressure, 02 engineering and technology, Blood Pressure/drug effects, valsartan, Double-Blind Method, 0202 electrical engineering, electronic engineering, information engineering, Antihypertensive Agents/therapeutic use, Humans, Valsartan/therapeutic use, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Antihypertensive Agents, Valsartan/adverse effects, Hypertension/physiopathology, Pyrimidines/adverse effects, Antihypertensive Agents/adverse effects, Biphenyl Compounds, Biphenyl Compounds/adverse effects, fimasartan, Middle Aged, 3. Good health, Pyrimidines, Treatment Outcome, Hypertension, placebo, Valsartan, Female, Angiotensin II Type 1 Receptor Blockers/adverse effects, Tetrazoles/adverse effects, Angiotensin II Type 1 Receptor Blockers, Hypertension/drug therapy
File Description: 1412~1421
Access URL: https://pubmed.ncbi.nlm.nih.gov/25092393
https://ir.ymlib.yonsei.ac.kr/handle/22282913/138743
https://pubmed.ncbi.nlm.nih.gov/25092393/
https://pure.ewha.ac.kr/en/publications/efficacy-and-safety-of-30-mg-fimasartan-for-the-treatment-of-pati
https://yonsei.pure.elsevier.com/en/publications/efficacy-and-safety-of-30-mg-fimasartan-for-the-treatment-of-pati
https://core.ac.uk/display/159800943
https://ewha.elsevierpure.com/en/publications/efficacy-and-safety-of-30-mg-fimasartan-for-the-treatment-of-pati -
16
Authors: et al.
Source: European Journal of Clinical Investigation; Vol 43
European Journal of Clinical Investigation, Vol. 43, No 12 (2013) pp. 1328-1338
European journal of clinical investigation
European Journal of Clinical InvestigationSubject Terms: ddc:616, Renin-Angiotensin System/drug effects/physiology, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Receptor, Angiotensin, Type 1/physiology, Aortic Aneurysm, Abdominal/drug therapy/etiology, Angiotensin-Converting Enzyme Inhibitors, Receptor, Angiotensin, Type 1, 3. Good health, Renin-Angiotensin System, Angiotensin-Converting Enzyme Inhibitors/therapeutic use, Disease Models, Animal, Mice, 03 medical and health sciences, 0302 clinical medicine, Animals, Humans, Angiotensin II Type 1 Receptor Blockers, Aortic Aneurysm, Abdominal, Forecasting
File Description: application/pdf
Access URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/eci.12173
https://pubmed.ncbi.nlm.nih.gov/24138426
https://core.ac.uk/display/54804585
https://archive-ouverte.unige.ch/unige:77524
https://onlinelibrary.wiley.com/doi/full/10.1111/eci.12173
https://www.ncbi.nlm.nih.gov/pubmed/24138426
https://onlinelibrary.wiley.com/doi/10.1111/eci.12173/full
https://biblio.ugent.be/publication/4186862
https://archive-ouverte.unige.ch/unige:77524
https://doi.org/10.1111/eci.12173
https://archive-ouverte.unige.ch/unige:77524
https://hdl.handle.net/11567/630163
https://doi.org/10.1111/eci.12173 -
17
Authors: et al.
Source: Renal Failure. 35:235-242
Subject Terms: Male, Heart failure - epidemiology, Hospitalization - statistics & numerical data, Angiotensin-Converting Enzyme Inhibitors, Coronary Artery Disease, Renal dialysis - mortality, Cohort Studies, 0302 clinical medicine, chronic - therapy, Treatment outcome, Angiotensin II type 1 receptor blockers - therapeutic use, Middle aged, chronic - diagnosis, Risk assessment, Middle Aged, Prognosis, 3. Good health, Hospitalization, Aspirin - therapeutic use, Angiotensin-converting enzyme inhibitors - therapeutic use, Cardiovascular Diseases, Diabetes mellitus - diagnosis, Diabetes mellitus - therapy, Adrenergic beta-antagonists - therapeutic use, Practice Guidelines as Topic, Cohort studies, Female, Guideline Adherence, Heart failure - drug therapy, Practice guidelines as topic, Cardiovascular diseases - drug therapy, Adrenergic beta-Antagonists, Kidney failure, Diabetes mellitus - epidemiology, 03 medical and health sciences, chronic - epidemiology, Diabetes Mellitus, Humans, Aged, Heart Failure, Cardiovascular agents - therapeutic use, Aspirin, Cardiovascular diseases - diagnosis, Heart failure - diagnosis, Guideline adherence, Cardiovascular Agents, Survival analysis, Coronary artery disease - epidemiology, Retrospective studies, Severity of illness index, Coronary artery disease - diagnosis, Cardiovascular diseases - epidemiology, Kidney Failure, Chronic, Renal dialysis - methods, Coronary artery disease - drug therapy, Angiotensin II Type 1 Receptor Blockers
-
18
Authors: et al.
Contributors: et al.
Source: Nephrology Dialysis Transplantation. 26:3722-3728
Subject Terms: Male, Chronic/complications, Brachial Artery, Tetrazoles, Valine/analogs & derivatives, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Valine/therapeutic use, Kidney Failure, 03 medical and health sciences, Vascular Stiffness, 0302 clinical medicine, Drug Therapy, endothelial function, Humans, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Prospective Studies, angiotensin receptor blocker, Vascular Resistance/drug effects, statin, Valine, Middle Aged, Prognosis, Chronic/therapy, 3. Good health, Vasodilation, Peritoneal Dialysis/adverse effects, arterial stiffness, Chronic/blood, Vascular Stiffness/drug effects, Vasodilation/drug effects, peritoneal dialysis, Tetrazoles/therapeutic use, Brachial Artery/drug effects, Combination, Kidney Failure, Chronic, Valsartan, Drug Therapy, Combination, Female, Vascular Resistance, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Angiotensin II Type 1 Receptor Blockers, Peritoneal Dialysis, Follow-Up Studies
File Description: 3722~3728
Access URL: https://academic.oup.com/ndt/article-pdf/26/11/3722/7634854/gfr108.pdf
https://pubmed.ncbi.nlm.nih.gov/21385862
https://academic.oup.com/ndt/article/26/11/3722/1830028
https://pubmed.ncbi.nlm.nih.gov/21385862/
https://yonsei.pure.elsevier.com/en/publications/combined-vascular-effects-of-hmg-coa-reductase-inhibitor-and-angi -
19
Authors: et al.
Contributors: et al.
Source: Holman, R R, Haffner, S M, McMurray, J J, Bethel, M A, Holzhauer, B, Hua, T A, Belenkov, Y, Boolell, M, Buse, J B, Buckley, B M, Chacra, A R, Chiang, F-T, Charbonnel, B, Chow, C-C, Davies, M J, Deedwania, P, Diem, P, Einhorn, D, Fonseca, V, Fulcher, G R, Gaciong, Z, Gaztambide, S, Giles, T, Horton, E, Ilkova, H, Jenssen, T, Kahn, S E, Krum, H, Laakso, M, Leiter, L A, Levitt, N S, Mareev, V, Martinez, F, Masson, C, Mazzone, T, Meaney, E, Nesto, R, Pan, C, Prager, R, Raptis, S A, Rutten, G E H M, Sandstroem, H, Schaper, F, Scheen, A, Schmitz, O, Sinay, I, Soska, V, Stender, S, Tamás, G, Tognoni, G & NAVIGATOR Study Group 2010, 'Effect of nateglinide on the incidence of diabetes and cardiovascular events', The New England Journal of Medicine, vol. 362, no. 16, pp. 1463-76. https://doi.org/10.1056/NEJMoa1001122
Subject Terms: Blood Glucose, Male, Valine/analogs & derivatives/therapeutic use, Tetrazoles, Nateglinide, Kaplan-Meier Estimate, Hypoglycemic Agents/adverse effects/therapeutic use, 0302 clinical medicine, Risk Factors, Blood Glucose/analysis/drug effects, Treatment Failure, Human health sciences, Pharmacy, pharmacology & toxicology, Cardiovascular Diseases/epidemiology/mortality/prevention & control, Incidence, Valine, Pharmacie, pharmacologie & toxicologie, Middle Aged, 16. Peace & justice, Glucose Intolerance/diet therapy/drug therapy/therapy, 3. Good health, Cardiovascular Diseases, Tetrazoles/therapeutic use, Drug Therapy, Combination, Female, Cyclohexanes/adverse effects/therapeutic use, Endocrinologie, métabolisme & nutrition, Angiotensin II Type 1 Receptor Blockers/therapeutic use, Phenylalanine, Systèmes cardiovasculaire & respiratoire, Sciences de la santé humaine, 03 medical and health sciences, Endocrinology, metabolism & nutrition, Double-Blind Method, Cyclohexanes, Cardiovascular & respiratory systems, Glucose Intolerance, Humans, Hypoglycemic Agents, Body Weight/drug effects, Exercise, Kaplan-Meiers Estimate, Proportional Hazards Models, Diabetes Mellitus, Type 2/epidemiology/prevention & control, Body Weight, Diabetes Mellitus, Type 2, Phenylalanine/adverse effects/analogs & derivatives/therapeutic use, Angiotensin II Type 1 Receptor Blockers, Follow-Up Studies
Access URL: https://cdr.lib.unc.edu/downloads/c247f1990
https://pubmed.ncbi.nlm.nih.gov/20228402
http://www.diva-portal.org/smash/record.jsf?pid=diva2:860270
https://research.monash.edu/en/publications/effect-of-nateglinide-on-the-incidence-of-diabetes-and-cardiovasc
https://www.ncbi.nlm.nih.gov/pubmed/20228402
http://eprints.gla.ac.uk/36560/
https://www.rdm.ox.ac.uk/publications/54714
http://orbi.ulg.ac.be/handle/2268/25946
https://ora.ox.ac.uk/objects/uuid:aa4c0e4f-29cf-402b-bd7d-5991a5da005c
https://doi.org/10.1056/nejmoa1001122 -
20
Authors: et al.
Source: Journal of Hypertension. 28(6):1134-1140
Subject Terms: Cardiology and Cardiovascular Disease, Kardiologi och kardiovaskulära sjukdomar, Aged, 80 and over, *Angioplasty, Balloon, Coronary, Angiotensin II Type 1 Receptor Blockers/*therapeutic use, Antihypertensive Agents/*therapeutic use, Humans, Hypertension/*drug therapy, Losartan/*therapeutic use, Middle Aged, Multivariate Analysis, Myocardial Infarction/*complications/surgery, Prognosis
Access URL: https://gup.ub.gu.se/publication/132228
Full Text 
Full Text Finder 
Nájsť tento článok vo Web of Science